[Skip to Content]
[Skip to Content Landing]
March 16, 2005

Estrogen Plus Progestin and Risk of Venous Thrombosis

JAMA. 2005;293(11):1322-1323. doi:10.1001/jama.293.11.1322-a

To the Editor: Dr Cushman and colleagues1 presented data from the Women’s Health Initiative (WHI) Estrogen Plus Progestin (E + P) trial and concluded that this combination was associated with increased risk for venous thromboembolism. The authors note that these results apply to the combination of oral conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA) and are not necessarily relevant to other types of hormone therapy; they describe the association with transdermal estrogen therapy as controversial.

First Page Preview View Large
First page PDF preview
First page PDF preview